Aragen News and Resources

Aragen, a global contract research, development and manufacturing organisation (CRDMO), has announced that its biologics manufacturing facility in Bangalore, India has completed facility and equipment qualification. The site is set to begin GMP production in late July 2025. The facility

Aragen, a Contract Research, Development and Manufacturing Organisation (CRDMO), has secured a $100 million investment from Quadria Capital, an Asia-focused private equity fund specialising in healthcare. The deal, which values Aragen at approximately $1.4 billion, includes a combination of fresh

Aragen, a Contract Research Development and Manufacturing Organisation (CRDMO) specialising in small molecules and biologics, has announced the operationalisation of the first phase of its biologics manufacturing facility in Bangalore, India. The $30 million facility has completed its inaugural small-scale